Proton Radiation Therapy for Acoustic Neuroma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using radiation to treat acoustic neuroma, a type of non-cancerous brain tumor. The focus is on fractionated proton radiation, designed to precisely target the tumor and minimize damage to surrounding healthy tissues. The goal is to determine if this method can better preserve hearing and control tumor growth compared to standard treatments. Eligible participants have a confirmed acoustic neuroma, have not received radiation treatment near their ear, and still maintain useful hearing in the affected ear. As a Phase 2 trial, the research measures how well the treatment works in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on losartan, other angiotensin II type I receptor blockers, ACE inhibitors, or medications known to cause ototoxicity (harm to the ear).
What prior data suggests that fractionated proton radiation is safe for treating acoustic neuroma?
Research has shown that fractionated proton radiation therapy is generally safe and well-tolerated. Studies have found that this treatment effectively controls tumor growth while minimizing side effects. For instance, one study found that patients with vestibular schwannomas (a type of non-cancerous brain tumor) who received this therapy experienced good tumor control with fewer side effects compared to traditional radiation treatments. Another study reported similar results, noting that patients handled the therapy well. Overall, fractionated proton radiation appears to be a promising and safe option for treating conditions like acoustic neuroma.12345
Why do researchers think this study treatment might be promising?
Fractionated proton radiation therapy is unique because it uses proton beams instead of traditional X-rays to target acoustic neuromas. Researchers are excited about this treatment because it may reduce side effects compared to conventional radiation therapy. Unlike standard treatments, which often affect surrounding healthy tissues, proton therapy delivers radiation more precisely, potentially sparing nearby structures and leading to fewer complications.
What evidence suggests that fractionated proton radiation is effective for acoustic neuroma?
Research has shown that fractionated proton radiation therapy effectively treats acoustic neuroma, a type of non-cancerous brain tumor. Studies have found that this treatment successfully controls the tumor, with success rates between 84% and 100%. This method also has few side effects, particularly in protecting important nerves, including those related to hearing. Patients receiving this treatment preserve their hearing better compared to traditional radiation methods. Overall, fractionated proton radiation therapy shows promise for managing tumor growth while minimizing side effects.26789
Who Is on the Research Team?
Helen A Shih, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for adults with measurable vestibular schwannoma who have 'useful hearing' and a life expectancy over 5 years. They must not have had prior radiotherapy near the internal acoustic canal, be on certain blood pressure medications, or have major ear diseases. Participants need to agree to use contraception and undergo regular hearing tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Proton radiation delivered daily using fractionated stereotactic radiotherapy (FSRT) for approximately 5.5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with visits 6 months after treatment and annually for 5 years
What Are the Treatments Tested in This Trial?
Interventions
- Fractionated proton radiation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Cancer Institute (NCI)
Collaborator